Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837997 | 0.85 | CA12 (0.55) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL23805051 | 0.85 | CA12 (0.50) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL17710407 | 0.85 | CA12 (0.50) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL28062695 | 0.82 | ALDH1A1 (0.52) | RAB9AALDH1A1HTTTSHRKMT2A | |
| SCHEMBL28949040 | 0.81 | NPC1 (0.52) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL27639509 | 0.81 | NPC1 (0.47) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL8380163 | 0.81 | ALDH1A1 (0.49) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL11064075 | 0.80 | KMT2A (0.56) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL17333394 | 0.78 | NPC1 (0.53) | CA12CA9NPC1RAB9AALDH1A1 | |
| SCHEMBL5144630 | 0.77 | MEN1 (0.58) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| CN-114174281-A | Degradation agent for cyclin dependent kinase 7(CDK7) and use thereof | 达纳-法伯癌症研究公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220056073-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2022-02-24 | — | — | US | disclosed |
| US-11203613-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY | 2021-12-21 | — | — | US | disclosed |
| US-20200317729-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | CORNELL UNIVERSITY | 2020-10-08 | — | — | US | disclosed |
| EP-3694605-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | Cornell University (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019075252-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-7884182-B2 | For assembling oligopeptide intermediates in chemical ligation reaction; prevents self-ligation; solid phase synthesis | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1511760-A2 | CARBOXY PROTECTION STRATEGIES FOR ACIDIC C-TERMINAL AMINO ACIDS IN CHEMICAL LIGATION OF OLIGOPEPTIDES | Geneprot, Inc. (CH) | 2005-03-09 | — | — | EP | disclosed |
| EP-0984925-B1 | COMPOUNDS, PREPARATION AND USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | disclosed |
| EP-1456225-A2 | EXTENDED NATIVE CHEMICAL LIGATION OF THREE OR MORE PEPTIDE FRAGMENTS | Geneprot, Inc. (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003042235-A9 | EXTENDED NATIVE CHEMICAL LIGATION OF THREE OR MORE PEPTIDE FRAGMENTS | GENEPROT INC (CH) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004007661-A2 | CARBOXY PROTECTION STRATEGIES FOR ACIDIC C-TERMINAL AMINO ACIDS IN CHEMICAL LIGATION OF OLIGOPEPTIDES | GENEPROT, INC. (CH) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003106615-A2 | POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION | GENEPROT, INC. (CH) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003042235-A2 | EXTENDED NATIVE CHEMICAL LIGATION OF THREE OR MORE PEPTIDE FRAGMENTS | GENEPROT, INC. (CH) | 2003-05-22 | — | — | WO | disclosed |
| US-6300321-B1 | LIPOPOLYAMINES | AVENTIS PHARMA S.A. (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-0984925-A1 | COMPOUNDS, PREPARATION AND USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS | Aventis Pharma S.A. (FR) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054130-A1 | COMPOUNDS, PREPARATION AND USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS | RHONE-POULENC RORER S.A. (FR) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317729-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | PSMB1, PSMB3, PSMB11 | CA12 4562/4885CA9 4312/4885NPC1 4062/4885 |
| US-20220056073-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | PSMB1, PSMB3, PSMB11 | CA12 4556/4885CA9 4300/4885NPC1 4075/4885 |
| US-11203613-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | CA12 4562/4885CA9 4312/4885NPC1 4062/4885 |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | CA12 4556/4885CA9 4300/4885NPC1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.